Document Detail

Bladder, bowel, and sexual dysfunction in Parkinson's disease.
Jump to Full Text
MedLine Citation:
PMID:  21918729     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Bladder dysfunction (urinary urgency/frequency), bowel dysfunction (constipation), and sexual dysfunction (erectile dysfunction) (also called "pelvic organ" dysfunctions) are common nonmotor disorders in Parkinson's disease (PD). In contrast to motor disorders, pelvic organ autonomic dysfunctions are often nonresponsive to levodopa treatment. The brain pathology causing the bladder dysfunction (appearance of overactivity) involves an altered dopamine-basal ganglia circuit, which normally suppresses the micturition reflex. By contrast, peripheral myenteric pathology causing slowed colonic transit (loss of rectal contractions) and central pathology causing weak strain and paradoxical anal sphincter contraction on defecation (PSD, also called as anismus) are responsible for the bowel dysfunction. In addition, hypothalamic dysfunction is mostly responsible for the sexual dysfunction (decrease in libido and erection) in PD, via altered dopamine-oxytocin pathways, which normally promote libido and erection. The pathophysiology of the pelvic organ dysfunction in PD differs from that in multiple system atrophy; therefore, it might aid in differential diagnosis. Anticholinergic agents are used to treat bladder dysfunction in PD, although these drugs should be used with caution particularly in elderly patients who have cognitive decline. Dietary fibers, laxatives, and "prokinetic" drugs such as serotonergic agonists are used to treat bowel dysfunction in PD. Phosphodiesterase inhibitors are used to treat sexual dysfunction in PD. These treatments might be beneficial in maximizing the patients' quality of life.
Ryuji Sakakibara; Masahiko Kishi; Emina Ogawa; Fuyuki Tateno; Tomoyuki Uchiyama; Tatsuya Yamamoto; Tomonori Yamanishi
Related Documents :
10128359 - Polyvinylchloride containers do not influence the hemodynamic response to intravenous n...
19404719 - Interleukin 8 gene polymorphisms and susceptibility to restenosis after percutaneous co...
3661369 - Merits and limitations of quantitative treadmill exercise score.
15979079 - The monocytic lineage specific soluble cd163 is a plasma marker of coronary atheroscler...
2076379 - Risk stratification after percutaneous transluminal coronary angioplasty.
20926949 - Serum choline levels in patients with stable angina and acute coronary syndromes: relat...
21083609 - Clinical significance of the highly sensitive fucosylated fraction of α-fetoprotein in...
17584719 - Prevalence of st-elevation in right precordial leads in patients presenting with acute ...
23993429 - Clinical and metabolic findings in patients with methionine adenosyltransferase i/iii d...
Publication Detail:
Type:  Journal Article     Date:  2011-09-12
Journal Detail:
Title:  Parkinson's disease     Volume:  2011     ISSN:  2042-0080     ISO Abbreviation:  Parkinsons Dis     Publication Date:  2011  
Date Detail:
Created Date:  2011-09-15     Completed Date:  2011-11-10     Revised Date:  2012-04-26    
Medline Journal Info:
Nlm Unique ID:  101539877     Medline TA:  Parkinsons Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  924605     Citation Subset:  -    
Neurology Division, Department of Internal Medicine, Sakura Medical Center, Toho University, 564-1 Shimoshizu, Sakura 285-8741, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Parkinsons Dis
Journal ID (publisher-id): PD
ISSN: 2090-8083
ISSN: 2042-0080
Publisher: SAGE-Hindawi Access to Research
Article Information
Download PDF
Copyright © 2011 Ryuji Sakakibara et al.
Received Day: 17 Month: 10 Year: 2010
Revision Received Day: 6 Month: 5 Year: 2011
Accepted Day: 30 Month: 5 Year: 2011
Print publication date: Year: 2011
Electronic publication date: Day: 12 Month: 9 Year: 2011
Volume: 2011E-location ID: 924605
ID: 3171780
PubMed Id: 21918729
DOI: 10.4061/2011/924605

Bladder, Bowel, and Sexual Dysfunction in Parkinson's Disease
Ryuji Sakakibara1*
Masahiko Kishi1
Emina Ogawa1
Fuyuki Tateno1
Tomoyuki Uchiyama2
Tatsuya Yamamoto2
Tomonori Yamanishi3
1Neurology Division, Department of Internal Medicine, Sakura Medical Center, Toho University, 564-1 Shimoshizu, Sakura 285-8741, Japan
2Department of Neurology, Chiba University, Chiba 263-8522, Japan
3Department of Urology, Dokkyo Medical University, Tochigi 321-0293, Japan
Correspondence: *Ryuji Sakakibara:
[other] Academic Editor: Irena Rektorova

1. Introduction

Parkinson's disease (PD) is a common movement disorder associated with the degeneration of dopaminergic neurons in the substantia nigra. In addition to the movement disorder, patients with PD often show nonmotor disorders. The nonmotor problems of PD include neuropsychiatric disorders, sleep disorders, sensory symptoms, and autonomic disorders [1]. Bladder, bowel, and sexual dysfunction (also called “pelvic organ” dysfunctions) is one of the most common autonomic disorders [2, 3]. Studies have shown that the pelvic organ dysfunctions have great significance in relation to quality-of-life measures, early institutionalization, and health economics [4, 5]. It is particularly important to note that, unlike motor disorder, pelvic organ dysfunctions are often nonresponsive to levodopa, suggesting that they occur through a complex pathomechanism [6]. This is because pathology of PD is not confined to the degeneration of dopaminergic neurons in the substantia nigra, and involves other locations in the brain and other neurotransmitter systems than the dopaminergic system. For this reason, add-on therapy is required to maximize patients' quality of life. This article reviews pelvic organ dysfunctions in PD, with particular reference to neural control of the bladder [2], bowel [2], and genital organs, symptoms, objective assessment, and treatment.

2. Bladder Dysfunction in PD
2.1. Neural Control of Micturition: Normal Micturition and Detrusor Overactivity

The lower urinary tract (LUT) consists of two major components, the bladder and urethra. The bladder has abundant muscarinic M2, 3 receptors and adrenergic beta 3 receptors, and is innervated by cholinergic (parasympathetic) and noradrenergic (sympathetic) fibers for contraction and relaxation, respectively [7]. The urethra has abundant adrenergic alpha 1A/D receptors and nicotinic receptors, and is innervated by noradrenergic (sympathetic; contraction) and cholinergic (somatic; contraction) fibers (Figure 1). The LUT performs two opposite functions, storage and emptying of urine, both of which require an intact neuraxis that involves almost all parts of the nervous system [8]. This is in contrast to postural hypotension, which arises due to lesions below the medullary circulation center in humans [9].

Normal urinary storage is dependent on the sacral autonomic reflex [7, 10]. The storage reflex is thought to be tonically facilitated by the brain, particularly the pontine storage center [11, 12]. The pontine storage center lies just ventrolateral to the pontine micturition center (PMC). In addition to the pontine storage center, the storage function is facilitated by the hypothalamus, cerebellum, basal ganglia, and frontal cortex. These areas have been shown to be activated during urinary storage by functional neuroimaging in humans [13]. Normal micturition is dependent on the spino-bulbo-spinal autonomic reflex [7], which particularly involves the midbrain periaqueductal gray matter (PAG) [1417] and the PMC [7, 11]. The PAG is thought to be central in regulating micturition and has a range of inputs from the higher structures. The PMC is located in or adjacent to the locus coeruleus [1820]. The PMC is thought to project spinal descending fibers containing glutamate as a facilitatory neurotransmitter, which activates the sacral bladder preganglionic nucleus [21]. PMC also projects fibers containing γ-amino-butyric acid (GABA) and glycine as inhibitory neurotransmitters, which suppresses the sacral urethral motor nucleus (the Onuf's nucleus) [22]. The voiding function seems to be initiated and facilitated by the higher brain structures, for example, the hypothalamus and prefrontal cortex, which seem to overlap in the storage-facilitating area [13, 23]. Bladder (detrusor) overactivity (DO) is the major cause of urinary urgency/frequency and incontinence [24]. In lesions above the brainstem, the micturition reflex arc is intact, where DO is considered an exaggerated micturition reflex [2426]. The exaggeration of the micturition reflex might be brought about by more than simply the decreased inhibition of the brain, and might be further facilitated by glutamatergic and D2 dopaminergic mechanisms [27].

2.2. Basal Ganglia Circuit and Dopamine

The net effect of the basal ganglia on micturition is thought to be inhibitory (Figure 2) [7, 2830]. Functional neuroimaging during bladder filling results in activation in the globus pallidus of normal volunteers [31] and in the putamen in patients with PD [32]. In contrast, dopamine transporter imaging was lower in PD patients with urinary dysfunction than in those without it [33, 34]. Electrical stimulation of the substantia nigra pars compacta (SNc) inhibited the micturition reflex [35, 36], and striatal dopamine levels in situ significantly increased in the urinary storage phase in experimental animals [37]. The micturition reflex is under the influences of dopamine (both inhibitory in D1 and facilitatory in D2) and GABA (inhibitory) [7, 28]. Both the SNc neuronal firing and the released striatal dopamine seem to activate the dopamine D1-GABAergic direct pathway (Figure 2), which not only inhibits the basal ganglia output nuclei, but also may inhibit the micturition reflex via GABAergic collateral to the micturition circuit [3740]. In patients with PD, disruption of this pathway may lead to DO and resultant urinary urgency/frequency. In addition to the nigrostriatal fibers, the ventral tegmental area (VTA)-mesolimbic dopaminergic fibers are thought to be involved in the control of micturition [36, 41, 42] (Figure 1).

2.3. Bladder Dysfunction in PD
2.3.1. Lower Urinary Tract Symptom

The reported prevalence of LUT symptoms (LUTS) in patients with PD ranges from 38% to 71% [4348]. However, it has been difficult to determine to what extent PD contributes to LUTS. Men older than 60 years of age may have bladder outlet obstruction due to prostate hyperplasia. Women may have stress urinary incontinence. “Idiopathic DO” [10] may occur in men and women older than 65 years due in part to latent brain ischemia [49]. Some of the studies were published before the diagnosis of multiple system atrophy (MSA) [50] was recognized. In recent studies of PD patients who were diagnosed according to modern criteria [5, 5153], the prevalence of LUTS was found to be 27–63.9% using validated questionnaires [5153], or 53% in men and 63% in women using a nonvalidated questionnaire that includes a urinary incontinence category [5], with all of these values being significantly higher than the incidence rates in healthy controls. The majority of patients had onset of bladder dysfunction after appearance of motor disorder. Correlations have been shown between bladder dysfunction in patients with PD and neurological disability [51], and bladder dysfunction and stage of disease [5], both suggesting a relationship between dopaminergic degeneration and LUTS. However, Campos-Sousa and colleagues did not find such a correlation [53].

2.3.2. Storage Symptoms

LUTS are divided majorly into two; storage symptoms and voiding symptoms. Storage symptoms are the most common of the LUTS symptom types in PD. Storage symptoms include nocturia (nighttime urinary frequency), which is the most prevalent symptom reported by patients with PD (>60%) [5, 5153]. Patients also complain of urinary urgency (33–54%) and daytime frequency (16–36%). Urinary incontinence was present in 26% of male and 28% of female patients with PD [5].

2.3.3. Voiding Symptoms

Although less common than storage symptoms, voiding symptoms also occur in PD patients. In the study by Sakakibara and colleagues, PD patients had significantly higher rates of retardation in initiating urination (44% of men only), prolongation/poor stream (70% of men only), and straining (28% of women only) compared with the control group [5]. Araki and colleagues noted a correlation between voiding symptoms and stage of disease [54]. However, despite the voiding symptoms, PD patients have low postvoid residuals [5].

2.3.4. Videourodynamics, Pressure-Flow Analysis, and Sphincter Electromyography

Bladder (Detrusor) Overactivity

The storage-phase urodynamic abnormalities in PD include reduced bladder capacity together with detrusor overactivity (DO) in 45–93% [43, 44, 5458] of patients, and uninhibited external sphincter relaxation in 33% [53] of patients (Figure 3). Therefore, DO can be the major contributing factor to overactive bladder in PD. There is also a correlation between DO and stage of disease [55].

Mild, Weak Detrusor, and Sphincter Obstruction

Pressure-flow analysis [10, 59, 60] of the voiding phase in PD has shown weak detrusor activity during voiding (40% of men; 66% of women) [56]. There is a correlation between a weak detrusor and the stage of the disease [55]. A subset of PD patients had DO during storage but weak detrusor activity in voiding. This combination has recently been estimated to occur in 18% of patients with PD [61]. Some older studies described detrusor-external sphincter dyssynergia or pseudodyssynergia in PD, and these findings were attributed to PD by analogy with bradykinesia of the limbs [62]. However, in our patients with PD, detrusor-external sphincter dyssynergia was rare [56]. In contrast, a pressure-flow analysis in PD revealed that half of the patients with PD showed mild urethral obstruction [56]. Patients with PD are reported to have high resting urethral pressure, probably as a result of medication—that is, levodopa and its metabolites, such as norepinephrine. Irrespective of voiding symptoms in PD, the average volume of postvoid residuals in PD was as small as 18 mL [56].

Differential Diagnosis of Parkinsonism by Bladder Dysfunction

In the differential diagnosis of PD and parkinsonian-type MSA, large postvoid residuals, open bladder neck, and neurogenic change in sphincter motor unit potentials are all common in MSA [56, 63] whereas they are rarely seen in clinically typical PD. However, recent evidence suggests that PD with dementia, or dementia with Lewy bodies [64], may have large postvoid residuals and neurogenic change in the sphincter motor unit potentials [65], thereby mimicking MSA.

2.4. Treatment of Bladder Dysfunction in PD
2.4.1. Dopaminergic Drugs

It is possible that levodopa and other antiparkinson medication may affect bladder function in PD. Aranda and Cramer [66] studied the effects of 3–8 mg apomorphine injection on the storage function in 2 de novo PD patients, and found that the bladder capacity increased. They gave oral levodopa to one of the patients, and the bladder capacity increased. We compared the frequency of bladder dysfunction in de novo PD and PD with levodopa. In that study, LUTS was less frequent than in the treated group [59]. In another study, after 3 months of treatment with levodopa, the storage urodynamic parameters were slightly improved in de novo PD [67].

In contrast, in treated patients, studies concerning the effect of dopaminergic drugs on micturition have produced conflicting results. Regarding overactive bladder, some reports have shown a storage-facilitating effect of dopaminergic drugs [5]. In contrast, Kuno and colleagues showed that a change in medication from bromocriptine (D2 selective agonist) to pergolide (D1 < 2 agonist) brought lessening of nocturia [68], and Yamamoto described improvement of DO by pergolide [69]. Benson and colleagues [70] gave 2000 mg of levodopa in 2 longstanding PD patients, and bladder capacity increased in both patients. After discontinuation of levodopa, the bladder capacity further increased in one of the patients, but decreased in the other. Other reports have shown a voiding-facilitating effect of dopaminergic drugs [71]. Fitzmaurice and colleagues [72] have described that, in advanced PD with the on-off phenomenon, DO worsened with levodopa in some patients and lessened in others. Winge and colleagues [73] found that the effect on micturition of treatment with dopaminergic drugs in PD was unpredictable. Recent studies have shown that in early PD [74] and advanced PD with the on-off phenomenon [6], a single dose of levodopa exacerbates DO in the filling phase. We still do not know the exact reasons for the discrepancy.

There are several factors underlying the complex bladder behavior in treated PD patients [75]. Postsynaptic dopamine D1 (excitatory) and D2 (inhibitory) receptors have a millimolar affinity to dopamine whereas dendritic D2 (inhibitory) autoreceptors have a picomolar affinity to dopamine [76]. Therefore, levodopa may first stimulate dendritic D2 autoreceptors, which might suppress the dopaminergic cells and facilitate the micturition reflex. In cases of PD under long-term treatment with levodopa, dopamine receptors are downregulated and potential hypersensitivity might occur [77]. The A11 dopaminergic cell group lies in the dorsal-posterior hypothalamus, which is affected in marmosets with MPTP-induced parkinsonism [78]. This cell group descends as the sole source of spinal dopamine [79], which might also involve in generating bladder overactivity [80]. Peripheral dopamine D1 and D2 receptors also exist in the bladder [81], although their exact role has not been delineated.

2.4.2. Cholinergic Drugs

Anticholinergics [82] are generally used as a first-line treatment for overactive bladder. However, it is important to balance the therapeutic benefits of these drugs with their potential adverse effects. When the dose of drug increases, postvoid residuals may appear [75]. Dry mouth and constipation are common [83]. Cognitive adverse events by anticholinergics are a concern particularly in the elderly. For example, trihexyphenidyl (for PD) and oxybutynin (for overactive bladder) have been shown to have central side effects [84, 85]. Factors contributing to the central effects of drugs may include blood-brain barrier (BBB) penetration [86]. Among the factors of BBB penetration, diffusion is facilitated by lipophilicity [87]. Particularly in elderly patients who have hallucinations or cognitive decline (PD with dementia/dementia with Lewy bodies) [64, 65], anticholinergics should be used with extreme caution.

2.4.3. Other Treatments

When a first-line treatment fails or is contraindicated, a second-line treatment might be considered. The main action of central 5-hydroxytryptamine- (5-HT, or serotonin-) ergic neurons on the LUT is facilitation of urine storage [88]. In PD, neuronal cell loss in the raphe nucleus has been documented [89]. Therefore, serotonergic drugs, such as duloxetine and milnacipran [90] can be a choice to treat overactive bladder in PD. Nocturnal polyuria should be distinguished from overactive bladder. In patients with PD, the imbalance between diurnal and nocturnal production of urine can be observed in the course of the disease [91]. Treatment with desmopressin proved to be effective in reducing nocturia in PD [92], although this medication needs caution of water intoxication. The subthalamic nucleus (STN) is regarded as the key area in the indirect pathway, which is dominant in the parkinsonian state [93]. Deep brain stimulation (DBS) in the STN inhibits many cells within the STN, probably due to depolarization block and release of GABA from activation of inhibitory afferent terminals [94]. In the STN, neuronal firings related to the micturition cycle have been observed in cats [39]. DBS in the STN proved to have an inhibitory effects on the micturition reflex in animals [39, 40] and in patients with PD [9597]. DBS in the STN also increased bladder capacity and facilitated bladder afferent pathways in the brain of PD patients [98, 99].

3. Bowel Dysfunction in PD
3.1. Neural Control of Defecation: Enteric Nervous System and Dopamine

The enteric nervous system (ENS) plays the most important role in regulating the peristaltic reflex of the lower gastrointestinal (GI) tract (LGIT) [100]. Slow phasic pressure waves are the most common manometric phenomenon [101], and are measured in the colon and rectum (spontaneous phasic rectal contraction) in humans [102105]. The origin of the slow wave rhythmicity in LGIT has been identified in the myenteric (Auerbach's) and submucous (Meisner's) plexuses, where interstitial cells of Cajal (ICC) exist [106]. The peristaltic reflex consists of two components: ascending contraction oral to, and descending relaxation caudal to, the site of stimulus (Figure 4). The reflex can be evoked by surface stroking or by circumferential stretch [100], in which 5-HT stimulates the sensory nerve terminals [107]. The oral excitatory component is mediated by cholinergic fibers whereas the aboral inhibitory component is mediated by nonadrenergic, noncholinergic fibers. Thus, local neuronal circuits and ICCs, together with appropriate external stimuli, might bring about the peristaltic reflex. Other types of pressure changes in the colon include giant motor complexes [100], which is perhaps analogous to the migrating motor complex of small intestine [100, 101]. After a meal, the motility index increases for 20 to 30 min and remains elevated for up to 3 hours. A combination of slow waves and giant motor complexes is thought to promote bowel transport, which is measured by colonic transit time (CTT) in humans [107, 108].

The strength of cholinergic transmission in the ENS is thought to be regulated by opposing receptors; serotonin 5-HT4 receptor-mediating excitation [109, 110] and dopamine D2 receptor-mediating inhibition [111, 112]. Endogenous 5-HT may facilitate intestinal motility [109], as colorectal motility is greater than normal in 5-HT transporter knockout mice with elevated extracellular 5-HT levels. Reports using dopamine transporter knockout mice have indicated that endogenous dopamine may inhibit intestinal motility [113, 114]. However, a number of studies have also demonstrated increased motility in the colon (scarce in dopamine receptors) in response to dopamine [115, 116], presumably mediated by other receptor populations such as adrenergic or serotonergic receptors, or by central mechanisms [116]. It is uncertain whether MPTP-induced parkinsonian animals might have enteric dopaminergic pathology as seen in PD [117121]. Nevertheless, MPTP/salsolinol-induced parkinsonian animals showed decreased GI motility [122] and decreased c-Kit expression in the ICC [123]. More recently, Dorolet and colleagues found myenteric plexus alpha-synuclein aggregate pathology, neuron loss, and slowing of gastrointestinal motility in rotenone-induced parkinsonian animals [124].

3.2. Extraenteric Nervous System and Dopamine

Whereas small intestine and ascending colon are innervated by the vagus nerves originating in the medulla, extraenteric innervation of descending colon, sigmoid colon, and rectum primarily shares that of the LUT (Figure 5) [7, 102]. LUT and LGIT perform the similar function of storage and emptying. However, there are also profound differences with regard to physiology (dysfunctional transport, rare ureter versus common bowel; smooth muscle contraction, only on emptying bladder contraction versus persistent spontaneous phasic rectal contraction; abdominal strain, minimum versus large, resp.) [102]. In addition, while the LUT requires intact neuraxis for storage and emptying [7], it has not been entirely clear to what extent LGIT needs extra-ENS.

Acute transection of the pelvic plexus shows slowed transit and abolishes the defecation reflex [125]. Six months later, the transit and defecation reflex are recovered [125]. In contrast, chronic replacement of esophagus [126] or bladder [127] by a colonic segment preserves colonic motility. Pathological studies in PD have shown a degenerative lesion in the spinal parasympathetic PGN [128], although the degree is much less than that in MSA. No Lewy bodies were found in the Onuf's nucleus innervating the anal sphincter [128]. Both the sacral cord and the vagus nuclei receive projecting fibers from Barrington's nucleus (identical to the PMC) in the pons. The spinal descending pathway for defecation is located in the lateral columns in humans [129, 130]. In the acute stage of spinal cord injury [131] or multiple sclerosis [132], CTT is significantly prolonged. In the chronic phase, prolonged CTT of the proximal colon returns to normal whereas that of the distal colon persists [133, 134]. Abdominal strain and cough are accompanied by sphincter contraction, which is called the guarding reflex [135]. However, when the sphincter contraction is large enough, defecation becomes unsuccessful as commonly seen in spinal cord injury (paradoxical sphincter contraction on defecation (PSCD) or anismus) [136]. In the brainstem, lesion in the vagus nuclei causes intestinal pseudo-obstruction [137, 138]. In PD, neuronal cell loss [139] and the appearance of Lewy bodies [128] in the vagus nuclei have been documented. Barrington's nucleus is thought to be critical to eliciting migrating motor complex [140, 141]. In PD, involvement of the Barrington's nucleus has also been documented [139].

The basal ganglia modulate the bowel motility [142, 143], with the main action apparently being inhibitory [142, 143]. However, under stress conditions, facilitatory responses were also observed [144, 145]. Although the connection is not fully clarified, bowel function seems to be modulated by the higher brain structures [146]. Most areas activated in functional neuroimaging by bowel distention [147] strikingly overlap the area activated by bladder distention [148].

3.3. Bowel Dysfunction in PD
3.3.1. Lower Gastrointestinal Tract Symptoms

In PD there is dysfunction along the entire length of the GI tract. Therefore, while we focus on the colon and rectum, we refer to stomach and small intestine when necessary. The reported prevalence of LGIT symptoms in PD is mostly more than half [149151]. However, it has been difficult to determine the extent to which PD is contributing to the LGIT symptoms. This difficulty occurs because not only PD but also idiopathic constipation may occur in the elderly due in part to dietary habit [151], exercise [152], or age-related ENS degeneration [153]. Controlled studies [5, 149, 154, 155] could overcome these problems, in which the incidence rate of decreased stool frequency (<3 times a week) in PD patients ranges from 20% to 81%, that of difficulty in stool expulsion in 57–67%, and that of diarrhea in 21%. All of these values are significantly higher than in the normal population (range, decreased stool frequency, 0–33%; difficulty in stool expulsion, 26–28%; diarrhea, 10%) [5, 149, 154, 155]. Fecal incontinence has been reported to be 10–24% in PD [5, 149]. Therefore, constipation is the most prominent LGIT symptoms in patients with PD. Indeed, PD is a risk factor for elderly nursing home residents to have constipation [156]. Of particular importance is that bowel dysfunction affects the quality of life in patients with PD [5].

There is no significant difference in the use of dopaminergic or anticholinergic drugs and bowel dysfunction [5, 149]. Difficulty in expulsion, and diarrhea are more common in the higher grade of Hoehn and Yahr staging [5, 149, 150], suggesting a relationship between dopaminergic degeneration and LGIT symptoms. However, there are also studies in which no such relationship was found [157]. Constipation in PD occurs commonly with a low coefficient of variation in electrocardiographic R to R intervals [158]. The findings indicate that parasympathetic dysfunction might underlie these abnormalities. A recent epidemiological study revealed an association between the frequency of bowel movements and the future risk of developing PD [159]. From a clinical perspective, it is of particular importance that patients with PD see gastroenterologists or physicians first because of their bowel dysfunction before a diagnosis of PD is made.

A more severe and often acute presentation of bowel dysfunction is intestinal pseudo-obstruction [160], also called paralytic ileus. Yokoyama and Hasegawa [161] have recently reported the frequency to be 7.1% among 112 patients with PD. Radiographical features of intestinal pseudo-obstruction are dilatation of colon and small intestine [160, 162164]. True obstruction due to volvulus in PD also occur [161, 163, 164]. Intestinal pseudo-obstruction also occurs insidiously [165, 166]. In such patients, histology specimens may reveal Lewy body disorder.

3.3.2. Lower Gastrointestinal Tract Function Tests

LGIT function primarily consists of (1) colonic transport of the bowel content to the anorectum [107, 108], (2) transient anorectum reservoir, and (3) defecation from the anorectum with the aid of strain [102]. In PD, constipation results primarily from decreased transport and/or disturbed anorectal evacuation. Fecal incontinence may result from disturbed anorectal reservoir, or overflow secondary to constipation.

3.3.3. Transit Time Study

Previous reports have shown that total CTT is increased beyond the normal threshold in 80% of PD patients [167], which translates into an increased average CTT ranging from 44 hours to 130 hours in PD [167, 168], and in 89 hours in de novo PD patients [167], all of which are significantly longer than those of controls (range, 20–39 hours) [160, 167, 168]. Prolonged CTT has also been documented in PD patients without subjective constipation [169]. Slow colonic transit is the major cause of decreased stool frequency. The slow colonic transit is likely to reflect a decrease in slow waves and spike activities of the colon, which may reflect the ENS pathology, and to a lesser extent, the CNS pathology in PD. Among right, left, and rectosigmoid segments of the CTT, the rectosigmoid CTT is significantly prolonged in PD patients [160, 167, 169]. Several explanations for this finding can be hypothesized. It is possible that the ENS innervated by the sacral cord is more severely affected than that innervated by the DMV in PD [160]. Oro-caecal transit time in PD is also prolonged [170].

Pathological studies have demonstrated that PD affects the ENS [117121]; showing decrease in dopaminergic myenteric neurons and the appearance of Lewy bodies along the proximal-distal axis, for example, they were most frequent in the lower esophagus, but scarce in the rectum. Presumably, degeneration of not only the inhibitory (dopaminergic) fibers, but also of facilitatory (cholinergic and serotonergic) fibers might contribute to the slow colonic transit in PD.

3.3.4. Rectoanal Videomanometry and Sphincter Electromyography

Resting State

Anal function at the resting state is measured by anal manometry and analysis of the external sphincter motor unit potentials. At the resting state, the anal pressure of PD patients is low or normal [160, 171]. The resting anal pressure may reflect sympathetic innervation in the internal anal sphincter, since lesions or anaesthetic blocks at T12-L3 (where the sympathetic PGN is located) substantially lessen the anal pressure [172]. Similarly, PD patients have low [173] or normal [160, 171] anal pressure increase on squeezing. However, neurogenic changes in motor unit potentials of the external sphincter muscles occur in only 0–15% of PD patients [174, 175]. This negative finding may correspond to the result of pathological studies indicating that the sacral Onuf's nucleus is spared in the majority of PD patients [128]. Nevertheless, the latent anal sphincter dysfunction may explain the fecal incontinence that occurs in most advanced cases. The rectoanal inhibitory reflex comprises a slow anal pressure decrease following a rapid distention of the intra-rectal balloon [176]. This reflex might be appropriate for evacuation. In PD, the threshold of the rectoanal inhibitory reflex is reduced [168, 171, 177] or normal. Although this reflex is thought to be mediated by the intrinsic ENS [178], the exact reflex arc is not entirely clear.

3.3.5. Filling Phase

Rectoanal videomanometry measures functions of the anorectum reservoir and evacuation. During slow rectal filling, PD patients have a slightly but not significantly larger rectal volume at first sensation and a maximum desire to defecate compared with control subjects [160, 171]. The PD patients had the same rectal compliance as control subjects using the slow-liquid-filling method [102, 160], which is in accordance with the studies using the balloon-inflation method. However, the amplitude of the spontaneous phasic rectal contraction in the PD patients is significantly less than that in control subjects [102, 160]. The decreased spontaneous phasic rectal contraction may share the same aetiology with the decrease in CTT.

In normal subjects, anal pressure not only varies during the storage phase, but also shows a close relation with spontaneous phasic rectal contraction, for example, when the rectal pressure increases, the anal pressure tends to decrease [102]. The concurrent sphincter relaxation with the spontaneous phasic rectal contraction resembles the rectoanal inhibitory reflex [176]. The concurrent sphincter relaxation might be appropriate for the following evacuation phase [102]. However, in the PD patients, both rectal and anal pressures tend to increase together [160]. This phenomenon during filling resembles the paradoxical sphincter contraction on defecation, as described below.

3.3.6. Defecation Phase

In addition to slow transit constipation, anorectal (outlet type) constipation is a common feature in PD. Indeed, most PD patients could not defecate completely and had postdefecation residuals, the volume of which were significantly larger than those in a control group [160]. During defecation, it has remained a subject of controversy whether true rectal contraction occurs, since abdominal strain is large enough to mask the rectal contraction if present. Only a few studies have measured the differential rectal pressure component [179] and not found rectal contraction on defecation. In recent studies, healthy control subjects had a moderate rectal pressure increase on defecation, for example, the healthy subjects utilized the final wave of spontaneous phasic rectal contractions for defecation [102]. However, rectal contraction on defecation in PD patients is smaller than that in controls [160].

The abdominal straining in PD patients is less than that in control subjects [160]. Straining plays a physiological role in both coughing and defecation, which is achieved by cocontraction of the glottis, diaphragm, and abdominal wall [180]. Straining is associated with activation in brainstem nuclei such as the Kolliker-Fuse nucleus and medullary respiratory neurons [180]. However, PD patients show a less pronounced increase in abdominal pressure on coughing [160, 181] and Valsalva maneuver [160, 182] before starting rectal filling, and in the defecation phase [160, 182], than do control subjects. The mechanism of the impaired straining in PD may include rigidity and reduced contractility of the axial muscles, and a failure of coordinated glottis closure [181]. However, neuronal degeneration in the CNS relevant to straining is yet to be clarified in PD.

During defecation, the anal pressure increase on defecation in patients is significantly larger than that in control subjects, with an increase in the sphincter electromyography (EMG) activity. This finding in PD has been described as paradoxical sphincter contraction on defecation (PSCD), or anismus [118, 160, 167, 171, 182, 183]. During fictive defecation (straining), a lack of anal inhibition has also been reported in 65% of PD patients. Although PSCD can also be seen in patients with idiopathic constipation [184], the frequent occurrence of PSCD in PD suggests that PSCD is a disease-related condition. The frequency of PSCD is almost the same in early and late PD [185], indicating that PSCD is an early defecatory abnormality. Mathers and colleagues [182] consider PSCD a focal dystonia. PSCD also occurs in spinal cord-injured patients [136], suggesting that dysfunction in the suprasacral descending pathway to the external sphincter is a contributing factor. Apomorphine is shown to lessen PSCD [182, 183]. This effect was not antagonized by domperidone, which did not penetrate the BBB, suggesting that the CNS pathology may produce PSCD. Both weak abdominal strain and PSCD seem to be the major causes of difficulty in stool expulsion in PD patients.

3.4. Treatment of Bowel Dysfunction in PD
3.4.1. Dietary Fibers

Although it is not certain whether exercise may facilitate bowel habit in PD, in the healthy population, moderate exercise is reported to shorten mouth-to-anus transit time [186] and improve overall wellbeing [152]. Water content is an important determinant to make stools normal (70% water) or hard (40–60% water) [184]. PD patients are reported to have reduced water intake [187]. Diet and laxatives are the first-line treatment for constipation [188]. Dietary fibers such as psyllium produced an improvement in stool consistency and an increase in stool frequency in healthy population [189] and PD [169, 190]. Polyethylene glycol 3350 [191], or bulking and highly hydrophilic agent polycarbophil [192], improve constipation in PD.

3.4.2. Cholinergic Drugs

A prior report has shown that pyridostigmine bromide, an acetylcholinesterase inhibitor, is effective in the amelioration of constipation in PD [193].

3.4.3. Dopaminergic Drugs

Levodopa and Other Dopaminergic Agonists

Dopamine is used as a peripheral vasoactive drug in intensive care units, in which dopamine is shown to reduce gastric migrating motor complex [194]. Dopamine also decreases gastric motility in normal volunteers [195] whereas it increases motility of the duodenum and sigmoid colon. Similarly, dopamine administration increases colonic motor activity in irritable bowel syndrome [196]. Unlike dopamine, levodopa penetrates the BBB [197]. However, it is possible that levodopa acts on the ENS and affects bowel function in PD, since levodopa can also be metabolized in the periphery. A modern formula utilizes levodopa in combination with peripheral dopa-decarboxylase inhibitor. This regimen could possibly reduce GI side effects [198]. However, no reports are available to see whether levodopa might change gut function in untreated PD patients. As for somatic sphincter function, levodopa improves voluntary anal squeezing in fluctuating PD patients, which parallels an improvement in gait difficulty from “off” to “on” stage [177]. Apomorphine, a dopaminergic agonist, has also been shown to lessen PSCD [182, 183]. This effect is not antagonized by domperidone, suggesting that apomorphine might act on the CNS dopaminergic pathways.

3.4.4. Dopaminergic Blockers

Dopaminergic blockers (domperidone, etc.) are widely used as GI prokinetics by means of antagonizing dopamine's inhibitory effects on the GI motility, particularly D2 receptor blockade [199]. The pharmacological profiles of the compounds differ in terms of their molecular structure, affinity at D2 receptors, and ability to interact with other receptor systems (5-HT3 and 5-HT4 receptors for metoclopramide; 5-HT4 receptors for levosulpiride). Since domperidone does not cross the BBB, it can be used as GI prokinetics for constipation in PD [200], although the effect of domperidone on constipation is minimal. In contrast, dopaminergic blockers that could penetrate the BBB (metoclopramide, levosulpiride, etc.) may potentially worsen extrapyramidal motor disorder in PD [199]. Since levodopa is absorbed from the small intestine [201], bowel dysfunction in PD may interfere with levodopa absorption, worsen the motor disorder, or even lead to malignant syndrome [202, 203]. Gastric emptying of an isotope-labeled solid meal becomes significantly faster during domperidone therapy in PD [200]. In addition, domperidone pretreatment causes a mean 12% increase in peak plasma levodopa concentrations that occurs a mean of 10 min earlier than when levodopa is given alone [202]. Peak plasma levodopa concentrations are reported to be greater on levodopa-domperidone than on levodopa-carbidopa [204].

3.4.5. Serotonergic Drugs

Cisapride, a selective 5-HT 4 receptor agonist, has significantly shortened CTT in PD [205], although after 1 year, only a small effect could be demonstrated [206]. Of particular importance is that cisapride add-on therapy improved the “on-off” phenomenon in advanced PD [203]. However, some reports indicated cisapride's D2 dopaminergic receptor blocking property [207]. Cisapride also blocks K+ channels and leads to cardiotoxicity. Mosapride is a novel selective 5-HT 4 receptor agonist that lacks a D2 receptor or K+ channel blocking property [208]. Mosapride is shown to ameliorate delayed gastric emptying [209] as well as constipation in PD [210], by shortening of total CTT (particularly the caudal segment), and by augmenting the amplitude in rectal contraction during defecation [210]. Improvement of parkinsonism is more significant with pergolide-mosapride than with pergolide-domperidone [211]. Tegaserod, a selective 5-HT 4 agonist, is also effective in ameliorating constipation in PD [212].

3.4.6. Other Drugs

Although prior reports have indicated the effectiveness of motilides (erythromycin, etc.) [213], neurotrophin-3 [214] and colchicine [215] on constipation in PD, their use remains limited. Type A botulinum toxin injection into the puborectalis muscle [216, 217] and biofeedback [218] ameliorates anismus in PD.

4. Sexual Dysfunction in PD
4.1. Neural Control of Erection: Normal Erection in Men

Sexual dysfunction is not uncommon in PD [5, 219223]. Studies have shown that sexual dysfunction has great significance in relation to quality-of-life measures. However, the detailed mechanism of sexual dysfunction in PD has not been well known.

The genital organ primarily shares lumbosacral innervation with the lower urinary tract. Erection is a vascular event [224]; occurring secondarily after dilatation of the cavernous helical artery and compression of the cavernous vein to the tunica albuginea [224]. Helical artery dilatation is brought about by activation of cholinergic and nitrergic nerves; this activation facilitates nitric oxide secretion from the vascular endothelium. Ejaculation is brought about by contraction of the vas deferens and the bladder neck, in order to prevent retrograde ejaculation, by activation of adrenergic nerves (Figure 6). Sexual intercourse in healthy men can be divided into 3 phases [225]: (a) desire (libido), (b) excitement and erection, and (c) orgasm, seminal emission from the vas deferens, and ejaculation from the penis. Erection can be further classified into 3 types by the relevant stimulation: (1) psychogenic erection (by audiovisual stimulation), (2) reflexive erection (by somatosensory stimulation), and (3) nocturnal penile tumescence (NPT; associated with rapid eye movement (REM-) sleep). “Morning erection” is considered the last NPT in the nighttime.

4.2. Hypothalamic Neurons and Dopamine in Men

Among the 3 types of erection, reflexive erection requires an intact sacral cord, particularly the intermediolateral (IML) cell columns. Pathology studies have shown that involvement of the IML nucleus is common in MSA, whereas it is uncommon in PD. Therefore, reflexive erection can be affected in patients with MSA. In patients with a supra-sacral spinal cord lesion, reflexive erection might be preserved, whereas psychogenic erection is severely disturbed because of a lesion in the spinal pathways to the sacral cord. Libido and erection are thought to be regulated by the hypothalamus; particularly the medial preoptic area (MPOA) and the paraventricular nucleus (PVN) (Figure 4) [226, 227]. Electrical or chemical stimulation in the MPOA/PVN evoked erection and mating behaviors in experimental animals, both of which were abolished by destruction of these areas. Somatosensory inputs from the genitalia ascend in the anterior spinal cord, and project to the MPOA/PVN via the thalamic nuclei. Erotic visual inputs from the retina are thought to reach the MPOA via the mamillary body. Recent neuroimaging studies have shown that penile stimulation or watching pornography activated these areas in humans [228]. NPT [229] seems to be regulated by the hypothalamic lateral preoptic area [230].

The raphe nucleus and the locus ceruleus are candidate areas participating in the regulation of NPT. Oxytocinergic neurons in the hypothalamic PVN are thought to facilitate erection by projecting directly to the sacral cord, and by projecting to the midbrain periaqueductal gray and the Barrington's nucleus (identical to the PMC). Serum oxytocin concentration increases during masturbation in healthy men.

In experimental animals, dopamine is known to facilitate erection and mating behaviors. The MPOA/PVN receives projections from the nigral dopaminergic neurons [231]. A microdialysis study showed that the dopamine concentration in the MPOA was increased by sexual stimulation. It is reported that dopamine D1/D2 receptors in the hypothalamus participate in erection whereas only D2 receptors participate in ejaculation. Pathology studies have shown that the hypothalamus is affected in PD [231]. Recently, polymorphism in the dopamine D4 receptor gene is shown to contribute to individual differences in human sexual behavior [232]. Prolactinergic neurons are thought to be inhibitory in sexual function. Serum prolactin levels increase after orgasm in healthy men. Prolactin-producing pituitary tumors often cause gynecomastia and erectile dysfunction in male patients. Hyperprolactinemia occurs after the use of sulpiride, metoclopramide, and chlorpromazine (all dopamine receptor antagonists). Therefore, dopaminergic neurons seem to facilitate oxytocinergic neurons whereas they inhibit prolactinergic neurons. Some de novo PD patients have hyper prolactinemia [233], which may contribute to erectile dysfunction in those patients.

4.3. Female Sexual Function and Dopamine

As compared with male genitalia, studies of female genital organs are limited. Vulva [234], clitoris [235] and vagina [236] primarily shares lumbosacral innervation with the lower urinary tract. Sexual arousal in women is a vasocongestive and neuromuscular event through these organs, paralleling genital lubrication, controlled by facilitatory parasympathetic (by vasoactive intestinal peptide, nitric oxide, and to a lesser extent acetylcholine, via the pelvic nerves from S2–4 intermediolateral (IML) cell column) and inhibitory sympathetic (by noradrenaline, via the hypogastric nerves from T12-L3 IML cell column,) inputs. Some information is thought to travel the vagal nerves. Activity of these spinal nuclei is controlled by sensory afferents from the genitalia and descending projections from the brain.

Like men, libido in women is thought to be regulated by the hypothalamus. The neural circuit for lordosis in animals involves a supraspinal loop, which is controlled by an estrogen- and progesterone-dependent signal, presumably at the ventromedial hypothalamus (VMH), medial preoptic area (MPOA), and paraventricular nucleus (PVN) in the hypothalamus. Lordosis is facilitated by lutenizing hormone-releasing factor (LHRH), alpha-melanocyte stimulating hormone (alpha-MSH), and methionine-enkephalin whereas suppressed by corticotrophin-releasing factor and beta-endorphin [237, 238]. Recent neuroimaging studies have shown that vaginal self-stimulation with/without orgasm activated these areas in humans [239]. Oxytocinergic neurons in the VMH and the MPOA are thought to facilitate vagino-clitorial sexual arousal and lordosis by projecting directly to the sacral cord [238, 240]. Role of dopamine in female sexual function remains not completely clear [241]. It is reported that lordosis was increased in female animals by microinjection of apomorphine (D1, 2 agonist) and quinpirole (D2 agonist) in the MPOA whereas it decreased by SKF 38393 (D1 agonist) [242]. This was counteracted by chemical inhibition of dopaminergic neurons in the ventral tegmental area (VTA) [243].

4.3.1. Male Sexual Symptoms

The reported prevalence of sexual symptoms in men with PD ranges from 37% to 65% [234239]. Only few previous studies have looked at sexual symptoms in PD and control subjects. Jacobs et al. [244] studied 121 men with PD (mean age 45 years) and 126 age- and sex-matched community male controls. Patients were more dissatisfied with their present sexual functioning and relationship whereas no differences were found for the frequency of sexual intercourse itself. Erection and ejaculation were not inquired. Sakakibara et al. [5] analyzed sexual function of 46 men with PD (age 35–70 years old) and 258 healthy male control subjects (age 30–70 years old) [5]. As compared with the control group, the frequency of dysfunction in PD patients was significantly higher for decrease of libido (84%), decrease of sexual intercourse (55%), decrease of orgasm (87%), and decrease of erection (79%) and ejaculation (79%). Therefore, sexual dysfunction is significant in PD. The majority of patients had onset of the sexual dysfunction after the appearance of the motor disorder. This is in contrast to patients with MSA, who often have sexual dysfunction before the onset of motor disorder.

Comparing the results between four age subgroups (subjects in their 30s, 40s, 50s, and 60s) in the control group, the frequencies of sexual intercourse and of orgasm were significantly lower in older individuals [5]. In the PD group, only the frequency of orgasm was lower in older men (P < 0.05). Comparing the results between both sexes in the control group, decrease of libido and orgasm were more common in women (P < 0.01). In the PD group, there was no significant difference in sexual function items. Bronner et al. [245] reported that use of medications (selective serotonin reuptake inhibitors used for comorbid depression), and advanced PD stage contributed to the development of ED.

4.3.2. Rigiscan

In healthy men, sexual intercourse is thought to be carried out by integrating affective, motor, sensory, autonomic, and other factors. In male patients with PD, depression, motor disorder, and pain inevitably lead to sexual dysfunction. In contrast, it has been difficult to determine to what extent autonomic factors contribute to the sexual dysfunction in PD. However, erectile dysfunction often precedes motor disorder in MSA, and abnormal NPT is not uncommon in PD. These findings strongly suggest that the disorder does in fact contribute to sexual dysfunction in PD. Rigiscan is an objective measure for erectile dysfunction, which allows both tumescence and rigidity measurement, and is suitable for assessing NPT.

Only few data have been available concerning the relationship between NPT and dopamine. However, in experimental animals, administration of levodopa elicited erection and yawning together. Animals with experimental parkinsonism showed fewer REM stages during sleep than control animals did.

4.3.3. Female Sexual Dysfunction

As compared with men, few studies are available concerning female sexual dysfunction in PD. Further, only few previous studies have looked at female sexual symptoms in PD and control subjects. Sakakibara et al. [5] analyzed sexual function of 38 women with PD (age 35–70 years old) and 98 healthy control women (age 30–70 years old) [5]. As compared with the control group, the frequency of dysfunction in women with PD was significantly higher for decrease of libido (83%) and decrease of sexual intercourse (88%) while decrease of orgasm was not different between women with PD and control. The majority of patients had onset of the sexual dysfunction after the appearance of the motor disorder. Welsh et al. [246] studied 27 women with PD (mean age 67 years) and community healthy controls, and in both group 50% were sexually active. As compared with control, women with PD had more common decrease of libido, vaginal tightness, involuntary urination, and dissatisfaction in sexual intercourse. There was no difference in terms of sexual arousal, sexual intercourse, and orgasm. Without control, in young PD patients (36–56 years) women had more common sexual problems (decrease of libido, 70%, decrease of sexual intercourse, 80%) than men (40%, 33.4%, resp.) [247, 248]. Other domains, such as loss of lubrication and pain, are not clearly known.

4.4. Treatment of Sexual Dysfunction in PD
4.4.1. Male Sexual Dysfunction

Dopaminergic Drugs

It is possible that levodopa and other antiparkinson medication may affect sexual function in PD. However, it is not entirely clear to what extent levodopa ameliorates sexual dysfunction in PD. In contrast, subcutaneous apomorphine injection is used to ameliorate fluctuating symptoms in PD. It has also been used to treat erectile dysfunction in the general population [247, 248] and in patients with PD [249], although the dose is different (general population, initial 2 mg and up to 3 mg [247, 248], PD, 4 mg [250]). Apomorphine is thought to stimulate dopamine D2 receptors, and activate oxytocinergic neurons in the PVN. Nausea is a common side effect of this drug. Cabergoline [251] and pergolide [252] are also reported to improve sexual dysfunction in PD. In contrast, pathological hypersexuality may occur together with [253] or without delirium [254], which is attributed to the dopamine dysregulation syndrome in this disorder. DBS in the STN has produced either improved sexual wellbeing [255] or transient mania with hypersexuality [256] in patients with PD.

Phosphodiesterase-5 Inhibitors

When dopaminergic drugs did not help, phosphodiesterase-5 inhibitors, for example, sildenafil, vardenafil, and so forth, become the first line treatment in PD [257, 258]. These drugs inhibit nitric oxide degradation and facilitate smooth muscle relaxation in the cavernous tissue. When treating PD patients with postural hypotension, these drugs should be prescribed with extreme caution [258].

Other Drugs

When phosphodiesterase-5 inhibitors did not help, recent trials of melanocortin, for example, melanotan-II, bremelanotide, and so forth, showed that these drugs might become a choice for treating erectile dysfunction. A group of pro-opio-melanocortin (POMC) gene products include adrenocorticotropic hormone (ACTH), α-melanocyte stimulating hormone (α-MSH), β-MSH, and γ-MSH. It is known that the arcuate nucleus of the hypothalamus projects POMC-containing neurons to the lateral hypothalamus, dorsal medial nucleus, MPOA, and PVN [22]. α-MSH as secreted in the MPOA and PVN participates in the central control of sexual function [21]. Bremelanotide is a melanocortin receptor agonist, and is reported to be effective for treating erectile dysfunction as compared with placebo [259].

4.4.2. Female Sexual Dysfunction

There is no established regimen to treat sexual dysfunction in women with PD. PDE5 inhibitors, such as sildenafil, tadalafil, and vardenafil, has become the first choice in the treatment of erectile dysfunction in men. Whereas sildenafil facilitated clitorial engorgement in women with sexual dysfunction [260], clinical efficacy of this drug in women with PD awaits further clarification [261]. Bremelanotide, a melanocortin receptor agonist, is applied to female sexual dysfunction, and is reported to be effective [262].

5. Conclusions

This article reviewed the current concepts of bladder, bowel, and sexual dysfunction (pelvic organ dysfunctions) in PD. Central nervous system pathology is clearly associated with bladder (urinary urgency/frequency) and sexual dysfunction (decrease in libido, erection, and overall dissatisfaction) in PD. In contrast, both central (weak strain and anismus) and peripheral myenteric pathology (slow colonic transit and loss of rectal contraction) are associated with bowel dysfunction. Anticholinergic agents are generally used to treat bladder dysfunction while phosphodiesterase inhibitors are used to treat sexual dysfunction. Dietary fibers, laxatives, and serotonergic agents are used to treat bowel dysfunction. These treatments are beneficial in maximizing patients' quality of life.

1. Chaudhuri KR,Healy DG,Schapira AHV. Non-motor symptoms of Parkinson’s disease: diagnosis and managementThe Lancet NeurologyYear: 200653235245
2. Sakakibara R,Uchiyama T,Yamanishi T,Shirai K,Hattori T. Bladder and bowel dysfunction in Parkinson’s diseaseJournal of Neural TransmissionYear: 2008115344346018327532
3. Magerkurth C,Schnitzer R,Braune S. Symptoms of autonomic failure in Parkinson’s disease: prevalence and impact on daily lifeClinical Autonomic ResearchYear: 2005152768215834763
4. McGrother CW,Jagger C,Clarke M,Castleden CM. Handicaps associated with incontinence: implications for managementJournal of Epidemiology and Community HealthYear: 19904432462482148771
5. Sakakibara R,Shinotoh H,Uchiyama T,et al. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson’s diseaseAutonomic Neuroscience: Basic and ClinicalYear: 2001921-27685
6. Uchiyama T,Sakakibara R,Hattori T,Yamanishi T. Short-term effect of a single levodopa dose on micturition disturbance in Parkinson’s disease patients with the wearing-off phenomenonMovement DisordersYear: 200318557357812722172
7. de Groat WC. Integrative control of the lower urinary tract: preclinical perspectiveBritish Journal of PharmacologyYear: 20061472S25S4016465182
8. Sakakibara R,Fowler CJ. Fowler CJBrain diseaseNeurologic Bladder, Bowel, and Sexual FunctionYear: 20011chapter 9Boston, Mass, USAElsevier98109 (WFN Seminars in Clinical Neurology).
9. Sakakibara R,Mori M,Fukutake T,Kita K,Hattori T. Orthostatic hypotension in a case with multiple sclerosisClinical Autonomic ResearchYear: 1997731631659232362
10. Abrams P,Cardozo L,Fall M,et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence SocietyNeurourology and UrodynamicsYear: 200221216717811857671
11. Blok BFM,Holstege G. The central control of micturition and continence: implications for urologyBJU InternationalYear: 199983, supplement 21610210596
12. Sakakibara R,Nakazawa K,Shiba K,et al. Firing patterns of micturition-related neurons in the pontine storage centre in catsAutonomic Neuroscience: Basic and ClinicalYear: 20029912430
13. Kavia RBC,Dasgupta R,Fowler CJ. Functional imaging and the central control of the bladderJournal of Comparative NeurologyYear: 20054931273216255006
14. Sakakibara R,Hattori T,Yasuda K,Yamanishi T,Tojo M,Mori M. Micturitional disturbance in Wernicke’s encephalopathyNeurourology and UrodynamicsYear: 19971621111159042673
15. Matsuura S,Allen GV,Downie JW. Volume-evoked micturition reflex is mediated by the ventrolateral periaqueductal gray in anesthetized ratsAmerican Journal of PhysiologyYear: 19982756R2049R20559843896
16. Liu Z,Sakakibara R,Nakazawa K,et al. Micturition-related neuronal firing in the periaqueductal gray area in catsNeuroscienceYear: 200412641075108215207340
17. Yaguchi H,Soma H,Miyazaki Y,et al. A case of acute urinary retention caused by periaqueductal grey lesionJournal of Neurology, Neurosurgery and PsychiatryYear: 200475812021203
18. Betts CD,Kapoor R,Fowler CJ. Pontine pathology and voiding dysfunctionBritish Journal of UrologyYear: 19927011001021638364
19. Sakakibara R,Hattori T,Yasuda K,Yamanishi T. Micturitional disturbance and the pontine tegmental lesion: urodynamic and MRI analyses of vascular casesJournal of the Neurological SciencesYear: 19961411-21051108880701
20. Sasaki M. Role of Barrington’s nucleus in micturitionJournal of Comparative NeurologyYear: 20054931212616255005
21. Matsumto G,Hisamitsu T,de Groat WC. Role of glutamate and NMDA receptors in the descending limb of the spinobulbospinal micturition reflex pathway of the ratNeuroscience LettersYear: 19951831-258617746488
22. Blok BFM,de Weerd H,Holstege G. The pontine micturition center projects to sacral cord GABA immunoreactive neurons in the catNeuroscience LettersYear: 19972332-31091129350844
23. Fowler CJ. Integrated control of lower urinary tract: clinical perspectiveBritish Journal of PharmacologyYear: 20061472S14S2416465178
24. Steers WD. Pathophysiology of overactive and urge urinary incontinenceReviews in UrologyYear: 20024, supplement 4S7S1816986023
25. Andersson KE. Mechanisms of disease: central nervous system involvement in overactive bladder syndromeNature Clinical Practice UrologyYear: 200412103108
26. Yokoyama O,Yotsuyanagi S,Akino H,Moriyama N,Matsuta Y,Namiki M. RNA synthesis in the pons necessary for maintenance of bladder overactivity after cerebral infarction in the ratJournal of UrologyYear: 200316951878188412686866
27. Yokoyama O,Yoshiyama M,Namiki M,de Groat WC. Changes in dopaminergic and glutamatergic excitatory mechanisms of micturition reflex after middle cerebral artery occlusion in conscious ratsExperimental NeurologyYear: 2002173112913511771945
28. Seki S,Igawa Y,Kaidoh K,Ishizuka O,Nishizawa O,Andersson KE. Role of dopamine D1 and D2 receptors in the micturition reflex in conscious ratsNeurourology and UrodynamicsYear: 200120110511311135387
29. Yoshimura N,Kuno S,Chancellor MB,de Groat WC,Seki S. Dopaminergic mechanisms underlying bladder hyperactivity in rats with a unilateral 6-hydroxydopamine (6-OHDA) lesion of the nigrostriatal pathwayBritish Journal of PharmacologyYear: 200313981425143212922929
30. Yoshimura N,Mizuta E,Yoshida O,Kuno S. Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeysJournal of Pharmacology and Experimental TherapeuticsYear: 199828612282339655864
31. Nour S,Svarer C,Kristensen JKI,Paulson OB,Law I. Cerebral activation during micturition in normal menBrainYear: 2000123478178910734009
32. Kitta T,Kakizaki H,Furuno T,et al. Brain activation during detrusor overactivity in patients with Parkinson’s disease: a positron emission tomography studyJournal of UrologyYear: 2006175399499816469600
33. Sakakibara R,Shinotoh H,Uchiyama T,Yoshiyama M,Hattori T,Yamanishi T. SPECT imaging of the dopamine transporter with [123I]-β-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson’s disease with urinary dysfunctionJournal of the Neurological SciencesYear: 20011871-2555911440745
34. Winge K,Friberg L,Werdelin L,Nielsen KK,Stimpel H. Relationship between nigrostriatal dopaminergic degeneration, urinary symptoms, and bladder control in Parkinson’s diseaseEuropean Journal of NeurologyYear: 2005121184285016241972
35. Yoshimura N,Sasa M,Yoshida O,Takaori S. Dopamine D-1 receptor-mediated inhibition of micturition reflex by central dopamine from the substantia nigraNeurourology and UrodynamicsYear: 1992115535545
36. Sakakibara R,Nakazawa K,Uchiyama T,Yoshiyama M,Yamanishi T,Hattori T. Micturition-related electrophysiological properties in the substantia nigra pars compacta and the ventral tegmental area in catsAutonomic Neuroscience: basic and ClinicalYear: 20021021-23038
37. Yamamoto T,Sakakibara R,Hashimoto K,et al. Striatal dopamine level increases in the urinary storage phase in cats: an in vivo microdialysis studyNeuroscienceYear: 2005135129930316111828
38. Smith Y,Bevan MD,Shink E,Bolam JP. Microcircuitry of the direct and indirect pathways of the basal gangliaNeuroscienceYear: 19988623533879881853
39. Sakakibara R,Nakazawa K,Uchiyama T,Yoshiyama M,Yamanishi T,Hattori T. Effects of subthalamic nucleus stimulation on the micturation reflex in catsNeuroscienceYear: 2003120387187512895527
40. Dalmose AL,Bjarkam CR,Sorensen JC,Djurhuus JC,Jorgensen TM. Effects of high frequency deep brain stimulation on urine storage and voiding function in conscious minipigsNeurourology and UrodynamicsYear: 200423326527215098225
41. Hashimoto K,Oyama T,Ukay Y,et al. Selective destruction of dopamine neurones of the ventral tegmental area, but not the substantia nigra, impairs reflex micturition in ratsNeurourology and UrodynamicsYear: 199716470471
42. Hashimoto K,Oyama T,Sugiyama T,Park YC,Kurita T. Neuronal excitation in the ventral tegmental area modulates the micturition reflex mediated via the dopamine D1 and D2 receptors in ratsJournal of Pharmacological SciencesYear: 200392214314812832842
43. Murnaghan GF. Neurogenic disorders of the bladder in ParkinsonismBritish Journal of UrologyYear: 19613340340914477379
44. Hattori T,Yasuda K,Kita K,Hirayama K. Voiding dysfunction in Parkinson’s diseaseJapanese Journal of Psychiatry and NeurologyYear: 19924611811861635308
45. Gray R,Stern G,Malone-Lee J. Lower urinary tract dysfunction in Parkinson’s disease: changes relate to age and not diseaseAge and AgeingYear: 19952464995048588540
46. Hald T,We B. The Urinary Bladder, Neurology and DynamicsYear: 1982Baltimore, Md, USAWilliams and Wilkins
47. Andersen JT. Disturbances of bladder and urethral function in Parkinson’s diseaseInternational Urology and NephrologyYear: 198517135413997405
48. Berger Y,Blaivas JG,DeLaRocha ER,Salinas JM. Urodynamic findings in Parkinson’s diseaseJournal of UrologyYear: 198713848368383656541
49. Sakakibara R,Hattori T,Uchiyama T,Yamanishi T. Urinary function in elderly people with and without leukoaraiosis: relation to cognitive and gait functionJournal of Neurology, Neurosurgery and PsychiatryYear: 1999675658660
50. Gilman S,Low PA,Quinn N,et al. Consensus statement on the diagnosis of multiple system atrophyJournal of the Autonomic Nervous SystemYear: 1998742-31891929915636
51. Araki I,Kuno S. Assessment of voiding dysfunction in Parkinson’s disease by the international prostate symptom scoreJournal of Neurology, Neurosurgery and PsychiatryYear: 2000684429433
52. Lemack GE,Dewey RB,Roehrborn CG,O’Suilleabhain PE,Zimmern PE. Questionnaire-based assessment of bladder dysfunction in patients with mild to moderate Parkinson’s diseaseUrologyYear: 200056225025410925088
53. Campos-Sousa RN,Quagliato E,da Silva BB,de Carvalho RM Jr.,Ribeiro SC,de Carvalho DF. Urinary symptoms in Parkinson’s disease: prevalence and associated factorsArquivos de Neuro-PsiquiatriaYear: 200361235936312894267
54. Araki I,Kitahara M,Oida T,Kuno S. Voiding dysfunction and Parkinson’s disease: urodynamic abnormalities and urinary symptomsJournal of UrologyYear: 200016451640164311025724
55. Stocchi F,Carbone A,Inghilleri M,et al. Urodynamic and neurophysiological evaluation in Parkinson’s disease and multiple system atrophyJournal of Neurology, Neurosurgery and PsychiatryYear: 1997625507511
56. Sakakibara R,Hattori T,Uchiyama T,Yamanishi T. Videourodynamic and sphincter motor unit potential analyses in Parkinson’s disease and multiple system atrophyJournal of Neurology, Neurosurgery and PsychiatryYear: 2001715600606
57. Pavlakis AJ,Siroky MB,Goldstein I,Krane RJ. Neurourologic findings in Parkinson’s diseaseJournal of UrologyYear: 1983129180836827689
58. Fitzmaurice H,Fowler CJ,Rickards D,et al. Micturition disturbance in Parkinson’s diseaseBritish Journal of UrologyYear: 19855766526564084724
59. Uchiyama T,Sakakibara R,Hattori T. Lower urinary tract dysfunctions of Parkinson’s disease model rat (6-hydroxydopamine treated rat) and effects of drugsAutonomic Nervous SystemYear: 2006434302308
60. Griffiths D. Basics of pressure-flow studiesWorld Journal of UrologyYear: 199513130337773315
61. Yamamoto T,Sakakibara R,Uchiyama T,et al. Neurological diseases that cause detrusor hyperactivity with impaired contractile functionNeurourology and UrodynamicsYear: 200625435636016532465
62. Pavlakis AJ,Siroky MB,Goldstein I,Krane RJ. Neurourologic findings in Parkinson’s diseaseJournal of UrologyYear: 1983129180836827689
63. Chandiramani VA,Palacej J,Fowlerj CJ. How to recognize patients with parkinsonism who should not have urological surgeryBritish Journal of UrologyYear: 19978011001049240187
64. McKeith IG,Dickson DW,Lowe J,et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortiumNeurologyYear: 200565121863187216237129
65. Sakakibara R,Ito T,Uchiyama T,et al. Lower urinary tract function in dementia of Lewy body typeJournal of Neurology, Neurosurgery and PsychiatryYear: 2005765729732
66. Aranda B,Cramer P. Effects of apomorphine and L-dopa on the parkinsonian bladderNeurourology and UrodynamicsYear: 19931232032098330043
67. Sakakibara R,Uchiyama T,Hattori T,Yamanishi T. Urodynamic evaluation in Parkinson’s disease before and after levodopa treatmentIn: Proceedings of the 9th International Catechecholamine Symposium2001Kyoto, Japan
68. Kuno S,Mizuta E,Yamasaki S,Araki I. Effects of pergolide on nocturia in Parkinson’s disease: three female cases selected from over 400 patientsParkinsonism and Related DisordersYear: 200410318118715036175
69. Yamamoto M. Pergolide improves neurogenic bladder in patients with Parkinson’s diseaseMovement DisordersYear: 199712p. 328
70. Benson GS,Raezer DM,Anderson JR,Saunders CD,Corrierie JN Jr.. Effect of levodopa on urinary bladderUrologyYear: 1976712428174263
71. Christmas TJ,Chapple CR,Lees AJ,et al. Role of subcutaneous apomorphine in parkinsonian voiding dysfunctionThe LancetYear: 198828626-862714511453
72. Fitzmaurice H,Fowler CJ,Rickards D,et al. Micturition disturbance in Parkinson’s diseaseBritish Journal of UrologyYear: 19855766526564084724
73. Winge K,Werdelin LM,Nielsen KK,Stimpel H. Effects of dopaminergic treatment on bladder function in Parkinson’s diseaseNeurourology and UrodynamicsYear: 200423768969615382192
74. Brusa L,Petta F,Pisani A,et al. Central acute D2 stimulation worsens bladder function in patients with mild Parkinson’s diseaseJournal of UrologyYear: 2006175120220616406911
75. Ishizuka O,Igawa Y,Nishizawa O,Andersson KE. Role of supraspinal tachykinins for volume-and L-dopa-induced bladder activity in normal conscious ratsNeurourology and UrodynamicsYear: 200019110110910602251
76. Cooper JR,Bloom FE,Roth RH. The Biochemical Basis of NeuropharmacologyYear: 20038th editionchapter 9Oxford, UKOxford University Press
77. Obeso JA,Olanow CW,Nutt JG. Levodopa motor complications in Parkinson’s diseaseTrends in NeurosciencesYear: 20002310S2S711052214
78. Gibb WRG,Lees AJ,Jenner P,Marsden CD. The dopamine neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces histological lesions in the hypothalamus of the common marmosetNeuroscience LettersYear: 198665179833486388
79. Clemens S,Rye D,Hochman S. Restless legs syndrome: revisiting the dopamine hypothesis from the spinal cord perspectiveNeurologyYear: 200667112513016832090
80. Ishizuka O,Mizusawa H,Nishizawa O. Roles of dopaminergic receptors in bladder and erectile function at the spinal levelAsian Journal of AndrologyYear: 20024428729012508130
81. El-Mas MM,Elmallah AI,Omar AG,Sharabi F. Dopamine modulates peripheral purinergic neurotransmission through multiple presynaptic receptors: tissue-dependent effectsPharmacological ResearchYear: 1999391111910051373
82. Wein AJ,Rackley RR. Overactive bladder: a better understanding of pathophysiology, diagnosis and managementJournal of UrologyYear: 20061753S5S1016458739
83. Abrams P,Andersson KE,Buccafusco JJ,et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladderBritish Journal of PharmacologyYear: 2006148556557816751797
84. Todorova A,Vonderheid-Guth B,Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous systemJournal of Clinical PharmacologyYear: 200141663664411402632
85. Kay GG,Abou-Donia MB,Messer WS,Murphy DG,Tsao JW,Ouslander JG. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patientsJournal of the American Geriatrics SocietyYear: 200553122195220116398909
86. Scheife R,Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderlyClinical TherapeuticsYear: 200527214415315811477
87. Andersson KE. Treatment of overactive bladder: other drug mechanismsUrologyYear: 2000555515710767453
88. Ito T,Sakakibara R,Nakazawa K,et al. Effects of electrical stimulation of the raphe area on the micturition reflex in catsNeuroscienceYear: 200614241273128016996219
89. Halliday GM,Blumbergs PC,Cotton RGH,Blessing WW,Geffen LB. Loss of brainstem serotonin- and substance P-containing neurons in Parkinson’s diseaseBrain ResearchYear: 199051011041071691042
90. Sakakibara R,Ito T,Uchiyama T,Awa Y,Yamaguchi C,Hattori T. Effects of milnacipran and paroxetine on overactive bladder due to neurologic diseases: a urodynamic assessmentUrologia InternationalisYear: 200881333533918931554
91. Hineno T,Mizobuchi M,Hiratani K,Inami Y,Kakimoto Y. Disappearance of circadian rhythms in Parkinson’s disease model induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in dogsBrain ResearchYear: 19925801-292991504821
92. Suchowersky O,Furtado S,Rohs G. Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson’s diseaseMovement DisordersYear: 19951033373407651453
93. Smith Y,Bevan MD,Shink E,Bolam JP. Microcircuitry of the direct and indirect pathways of the basal gangliaNeuroscienceYear: 19988623533879881853
94. Dostrovsky JO,Lozano AM. Mechanisms of deep brain stimulationMovement DisordersYear: 2002173S63S6811948756
95. Finazzi-Agrò E,Peppe A,d’Amico A,et al. Effects of subthalamic nucleus stimulation on urodynamic findings in patients with Parkinson’s diseaseJournal of UrologyYear: 200316941388139112629368
96. Seif C,Herzog J,van der Horst C,et al. Effect of subthalamic deep brain stimulation on the function of the urinary bladderAnnals of NeurologyYear: 200455111812014705120
97. Winge K,Nielsen KK,Stimpel H,Lokkegaard A,Jensen SR,Werdelin L. Lower urinary tract symptoms and bladder control in advanced Parkinson’s disease: effects of deep brain stimulation in the subthalamic nucleusMovement DisordersYear: 200722222022517133504
98. Herzog J,Weiss PH,Assmus A,et al. Subthalamic stimulation modulates cortical control of urinary bladder in Parkinson’s diseaseBrainYear: 2006129123366337517077105
99. Herzog J,Weiss PH,Assmus A,et al. Improved sensory gating of urinary bladder afferents in Parkinson’s disease following subthalamic stimulationBrainYear: 2008131113214517977862
100. Hansen MB. Neurohumoral control of gastrointestinal motilityPhysiological ResearchYear: 200352113012625803
101. Kellow JE,Delvaux M,Azpiroz F,Camilleri M,Quigley EMM,Thompson DG. Principles of applied neurogastroenterology: physiology/motility-sensationGutYear: 19994521724
102. Ito T,Sakakibara R,Uchiyama T,Zhi L,Yamamoto T,Hattori T. Videomanometry of the pelvic organs: a comparison of the normal lower urinary and gastrointestinal tractsInternational Journal of UrologyYear: 2006131293516448429
103. Read NW,Haynes WG,Bartolo DCC,et al. Use of anorectal manometry during rectal infusion of saline to investigate sphincter function in incontinent patientsGastroenterologyYear: 1983851051136852445
104. Thorpe AC,Roberts JP,Williams NS,Blandy JP,Badenoch DF. Pelvic floor physiology in women with faecal incontinence and urinary symptomsBritish Journal of SurgeryYear: 19958221731767749679
105. Broens P,Vanbeckevoort D,Bellon E,Penninckx F. Combined radiologic and manometric study of rectal filling sensationDiseases of the Colon and RectumYear: 20024581016102212195184
106. Amborova P,Hubka P,Ulkova I,Hulin I. The pacemaker activity of interstitial cells of cajal and gastric electrical activityPhysiological ResearchYear: 200352327528412790758
107. Couturier D,Chaussade S. Total and segmental colonic transit times: measurement by radio-opaque markersPresse MedicaleYear: 19881726973
108. Bassotti G,de Roberto G,Castellani D,Sediari L,Morelli A. Normal aspects of colorectal motility and abnormalities in slow transit constipationWorld Journal of GastroenterologyYear: 200511182691269615884105
109. Liu MT,Rayport S,Jiang L,Murphy DL,Gershon MD. Expression and function of 5-HT3 receptors in the enteric neurons of mice lacking the serotonin transporterAmerican Journal of PhysiologyYear: 20022836G1398G141112388212
110. Tonini M. 5-hydroxytryptamine effects in the gut: the 3, 4, and 7 receptorsNeurogastroenterology and MotilityYear: 200517563764216185301
111. Walker JK,Gainetdinov RR,Mangel AW,Caron MG,Shetzline MA. Mice lacking the dopamine transporter display altered regulation of distal colonic motilityAmerican Journal of PhysiologyYear: 20002792G311G31810915639
112. Anlauf M,Schafer MKH,Eiden L,Weihe E. Chemical coding of the human GI nervous system: cholinergic, VIPergic, and catecholaminergic phenotypesJournal of Comparative NeurologyYear: 200345919011112629668
113. Gainetdinov RR,Jones SR,Fumagalli F,Wightman RM,Caron MG. Re-evaluation of the role of the dopamine transporter in dopamine system homeostasisBrain Research ReviewsYear: 1998262-31481539651511
114. Zhi SL,Schmauss C,Cuenca A,Ratcliffe E,Gershon MD. Physiological modulation of intestinal motility by enteric dopaminergic neurons and the D2 receptor: analysis of dopamine receptor expression, location, development, and function in wild-type and knock-out miceJournal of NeuroscienceYear: 200626102798280716525059
115. Wiley J,Owyang C. Dopaminergic modulation of rectosigmoid motility: action of domperidoneJournal of Pharmacology and Experimental TherapeuticsYear: 198724225485513612550
116. Vaughan CJ,Aherne AM,Lane E,Power O,Carey RM,O’Connell DP. Identification and regional distribution of the dopamine D1A receptor in the gastrointestinal tractAmerican Journal of PhysiologyYear: 20002792R599R60910938251
117. Qualman SJ,Haupt HM,Yang P,Hamilton SR. Esophageal Lewy bodies associated with ganglion cell loss in achalasia. Similarity to Parkinson’s diseaseGastroenterologyYear: 19848748488566088351
118. Kupsky WJ,Grimes MM,Sweeting J,Bertsch R,Cote LJ. Parkinson’s disease and megacolon: concentric hyaline inclusions (Lewy bodies) in enteric ganglion cellsNeurologyYear: 1987377125312553037441
119. Wakabayashi K,Takahachi H,Ohama E,Ikuta F. Parkinson’s disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous systemActa NeuropathologicaYear: 19907965815831972853
120. Takeda S,Yamazaki K,Miyakawa T,Arai H. Parkinson’s disease with involvement of the parasympathetic gangliaActa NeuropathologicaYear: 19938643973988256591
121. Singaram C,Ashraf W,Gaumnitz EA,et al. Dopaminergic defect of enteric nervous system in Parkinson’s disease patients with chronic constipationThe LancetYear: 19953468979861864
122. Haskel Y,Hanani M. Inhibition of gastrointestinal motility by MPTP via adrenergic and dopaminergic mechanismsDigestive Diseases and SciencesYear: 19943911236423677956604
123. Banach T,Zurowski D,Gil K,Krygowska-Wajs A,Marszalek A,Thor PJ. Peripheral mechanisms of intestinal dysmotility in rats with salsolinol induced experimental Parkinson’s diseaseJournal of Physiology and PharmacologyYear: 200657229130016845232
124. Drolet RE,Cannon JR,Montero L,Greenamyre JT. Chronic rotenone exposure reproduces Parkinson’s disease gastrointestinal neuropathologyNeurobiology of DiseaseYear: 20093619610219595768
125. Tanaka T,VanKlompenberg LH,Sarr MG. Selective role of vagal and nonvagal innervation in initiation and coordination of gastric and small bowel patterns of interdigestive and postprandial motilityJournal of Gastrointestinal SurgeryYear: 20015441843311985985
126. Dantas RO,Mamede RCM. Motility of the transverse colon used for esophageal replacementJournal of Clinical GastroenterologyYear: 200234322522811873100
127. El-Bahnasawy MS,Osman Y,Gomha MA,Shaaban AA. Persistent and occasional nocturnal enuresis in orthotopic urinary diversion: is there a urodynamic difference?BJU InternationalYear: 20059691373137716287461
128. Wakabayashi K,Takahashi H. Neuropathology of autonomic nervous system in Parkinson’s diseaseEuropean NeurologyYear: 199738 supplement 2279387796
129. Nathan PW,Smith MC. Spinal pathways subserving defaecation and sensation from the lower bowelJournal of Neurology, Neurosurgery and PsychiatryYear: 1953164245256
130. Kanesaka T,Sakakibara R,Ito S,et al. Intestinal pseudo-obstruction in acute myelitisInternal MedicineYear: 2006451353616467605
131. Lynch AC,Frizelle FA. Colorectal motility and defecation after spinal cord injury in humansProgress in Brain ResearchYear: 200515233534316198711
132. Chia YW,Gill KP,Jameson JS,et al. Paradoxical puborectalis contraction is a feature of constipation in patients with multiple sclerosisJournal of Neurology, Neurosurgery and PsychiatryYear: 19966013135
133. Krogh K,Mosdal C,Laurberg S. Gastrointestinal and segmental colonic transit times in patients with acute and chronic spinal cord lesionsSpinal CordYear: 2000381061562111093323
134. Sakakibara R,Yamaguchi T,Uchiyama T,et al. Calcium polycarbophil improves constipation in non-traumatic spinal cord disordersClinical Autonomic ResearchYear: 200616428929216810464
135. Park JM,Bloom DA,McGuire EJ. The guarding reflex revisitedBritish Journal of UrologyYear: 19978069409459439415
136. Nout YS,Leedy GM,Beattie MS,Bresnahan JC. Alterations in eliminative and sexual reflexes after spinal cord injury: defecatory function and development of spasticity in pelvic floor musculatureProgress in Brain ResearchYear: 200515235937216198713
137. Wood JR,Camilleri M,Low PA,Malagelada JR. Brainstem tumor presenting as an upper gut motility disorderGastroenterologyYear: 1985896141114144054533
138. Ito T,Sakakibara R,Sakakibara Y,Mori M,Hattori T. Medulla and gutInternal MedicineYear: 20044311p. 1091
139. Gai WP,Blessing WW,Blumbergs PC. Ubiquitin-positive degenerating neurites in the brainstem in Parkinson’s diseaseBrainYear: 19951186144714598595476
140. Weber J,Denis P,Mihout B,et al. Effect of brain-stem lesion on colonic and anorectal motility: study of three patientsDigestive Diseases and SciencesYear: 19853054194253987475
141. Valentino RJ,Kosboth M,Colflesh M,Miselis RR. Transneuronal labeling from the rat distal colon: anatomic evidence for regulation of distal colon function by a pontine corticotropin-releasing factor systemJournal of Comparative NeurologyYear: 2000417439941410701863
142. Gravante G,Sabatino M,Sorbera F,Ferraro G,La Grutta V. Effects of substantia nigra stimulation on electrical and mechanical activities of the duodeno-jejunal loop, in the catArchives Internationales de Physiologie et de BiochimieYear: 1985932931002412517
143. Jing H,Lin KW,Mei MH. Participation of dopamine on the muscarinergic inhibitory effect of substance P on gastric myoelectric activity and motilitySheng Li Xue BaoYear: 19954732452527570109
144. Gibb WRG,Lees AJ,Jenner P,Marsden CD. The dopamine neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces histological lesions in the hypothalamus of the common marmosetNeuroscience LettersYear: 198665179833486388
145. Bueno L,Gue M,Fabre C,Junien JL. Involvement of central dopamine and D1 receptors in stress-induced colonic motor alterations in ratsBrain Research BulletinYear: 19922921351401356067
146. Bagaev V,Aleksandrov V. Visceral-related area in the rat insular cortexAutonomic Neuroscience: Basic and ClinicalYear: 20061251-21621
147. Jones MP,Dilley JB,Drossman D,Crowell MD. Brain-gut connections in functional GI disorders: anatomic and physiologic relationshipsNeurogastroenterology and MotilityYear: 20061829110316420287
148. Kavia RBC,Dasgupta R,Fowler CJ. Functional imaging and the central control of the bladderJournal of Comparative NeurologyYear: 20054931273216255006
149. Edwards LL,Pfeiffer RF,Quigley EMM,Hofman R,Balluff M. Gastrointestinal symptoms in Parkinson’s diseaseMovement DisordersYear: 1991621511562057006
150. Jost WH. Autonomic dysfunction in idiopathic Parkinson’s diseaseJournal of NeurologyYear: 2003250, supplement 1I28I3012761632
151. Magerkurth C,Schnitzer R,Braune S. Symptoms of autonomic failure in Parkinson’s disease: prevalence and impact on daily lifeClinical Autonomic ResearchYear: 2005152768215834763
152. Tuteja AK,Talley NJ,Joos SK,Woehl JV,Hickam DH. Is constipation associated with decreased physical activity in normally active subjects?American Journal of GastroenterologyYear: 2005100112412915654791
153. Wiley JW. Aging and neural control of the GI tract III: senescent enteric nervous system: lessons from extraintestinal sites and nonmammalian speciesAmerican Journal of PhysiologyYear: 20022835G1020G102612381514
154. Singer C,Weiner WJ,Sanchez-Ramos JR. Autonomic dysfunction in men with Parkinson’s diseaseEuropean NeurologyYear: 19923231341401592069
155. Siddiqui MF,Rast S,Lynn MJ,Auchus AP,Pfeiffer RF. Autonomic dysfunction in Parkinson’s disease: a comprehensive symptom surveyParkinsonism and Related DisordersYear: 20028427728412039423
156. Robson KM,Kiely DK,Lembo T. Development of constipation in nursing home residentsDiseases of the Colon and RectumYear: 200043794094310910239
157. Jost WH,Schimrigk K. Constipation in Parkinson’s diseaseKlinische WochenschriftYear: 199169209069091795497
158. Wang SJ,Fuh JL,Shan DE,et al. Sympathetic skin response and R-R interval variation in Parkinson’s diseaseMovement DisordersYear: 1993821511578474481
159. Abbott RD,Petrovitch H,White LR,et al. Frequency of bowel movements and the future risk of Parkinson’s diseaseNeurologyYear: 200157345646211502913
160. Sakakibara R,Odaka T,Uchiyama T,et al. Colonic transit time and rectoanal videomanometry in Parkinson’s diseaseJournal of Neurology, Neurosurgery and PsychiatryYear: 2003742268272
161. Yokoyama T,Hasegawa I. Ileus in Parkinson’s diseaseNeurological MedicineYear: 200766611
162. Lewitan A,Nathanson L,Slade WR Jr.. Megacolon and dilatation of the small bowel in parkinsonismGastroenterologyYear: 195117336737414823189
163. Caplan LH,Jacobson HG,Rubinstein BM,Rotman MZ. Megacolon and volvulus in Parkinson’s diseaseRadiologyYear: 196585737914303073
164. Rosenthal MJ,Marshall CE. Sigmoid volvulus in association with parkinsonism: report of four casesJournal of the American Geriatrics SocietyYear: 19873576836843584772
165. de Giorgio R,Guerrini S,Barbara G,Cremon C,Stanghellini V,Corinaldesi R. New insights into human enteric neuropathyNeurogastroenterology and MotilityYear: 200416, supplement 114314715066021
166. Bassotti G,Villanacci V. Slow transit constipation: a functional disorder becomes an enteric neuropathyWorld Journal of GastroenterologyYear: 200612294609461316937428
167. Jost WH,Schrank B. Defecatory disorders in de novo Parkinsonians: colonic transit and electromyogram of the external anal sphincterWiener Klinische WochenschriftYear: 1998110155355379782572
168. Edwards LL,Quigley EMM,Harned RK,Hofman R,Pfeiffer RF. Characterisation of swallowing and defecation in Parkinson’s diseaseThe American Journal of GastroenterologyYear: 19948915258273792
169. Ashraf W,Pfeiffer RF,Park F,Lof J,Quigley EMM. Constipation in Parkinson’s disease: objective assessment and response to psylliumMovement DisordersYear: 19971269469519399219
170. Davies KN,King D,Billington D,Barrett JA. Intestinal permeability and orocaecal transit time in elderly patients with Parkinson’s diseasePostgraduate Medical JournalYear: 1996728451641678731708
171. Stocchi F,Carbone A,Inghilleri M,et al. Urodynamic and neurophysiological evaluation in Parkinson’s disease and multiple system atrophyJournal of Neurology, Neurosurgery and PsychiatryYear: 1997625507511
172. Frenckner B,Ihre T. Influence of autonomic nerves on the internal anal sphincter in manGutYear: 1976174306312773793
173. Edwards LL,Quigley EMM,Harned RK,Hofman R,Pfeiffer RF. Defecatory function in Parkinson’s disease: response to apomorphineAnnals of NeurologyYear: 19933354904938498826
174. Sakakibara R,Hattori T,Uchiyama T,Yamanishi T. Videourodynamic and sphincter motor unit potential analyses in Parkinson’s disease and multiple system atrophyJournal of Neurology, Neurosurgery and PsychiatryYear: 2001715600606
175. Paviour DC,Williams D,Fowler CJ,Quinn NP,Lees AJ. Is sphincter electromyography a helpful investigation in the diagnosis of multiple system atrophy? A retrospective study with pathological diagnosisMovement DisordersYear: 200520111425143016007638
176. Kamm MA. Kamm MA,Lennard-Jones JEPelvic floor testsConstipationYear: 1994chapter 17Petersfield, UKWrightson Biomedical Publishing145153
177. Ashraf W,Wszolek ZK,Pfeiffer RF,et al. Anorectal function in fluctuating (on-off) Parkinson’s disease: evaluation by combined anorectal manometry and electromyographyMovement DisordersYear: 19951056506578552119
178. de Lorijn F,de Jonge WJ,Wedel T,Vanderwinden JM,Benninga MA,Boeckxstaens GE. Interstitial cells of Cajal are involved in the afferent limb of the rectoanal inhibitory reflexGutYear: 20055481107111316009682
179. MacDonald A,Paterson PJ,Baxter JN,Finlay IG. Relationship between intra-abdominal and intrarectal pressure in the proctometrogramBritish Journal of SurgeryYear: 1993808107010718402072
180. Iscoe S. Control of abdominal musclesProgress in NeurobiologyYear: 19985644335069775401
181. Fontana GA,Pantaleo T,Lavorini F,Benvenuti F,Gangemi S. Defective motor control of coughing in Parkinson’s diseaseAmerican Journal of Respiratory and Critical Care MedicineYear: 199815824584649700121
182. Mathers SE,Kempster PA,Law PJ,et al. Anal sphincter dysfunction in Parkinson’s diseaseArchives of NeurologyYear: 19894610106110642803065
183. Edwards L,Quigley EMM,Hofman R,Pfeiffer RF. Gastrointestinal symptoms in Parkinson disease: 18-month follow-up studyMovement DisordersYear: 19938183868093549
184. Read NW,Timms JM. Defecation and the pathophysiology of constipationClinics in GastroenterologyYear: 19861549379653536215
185. Bassotti G,Maggio D,Battaglia E,et al. Manometric investigation of anorectal function in early and late stage Parkinson’s diseaseJournal of Neurology, Neurosurgery and PsychiatryYear: 2000686768770
186. Oettle GJ. Effect of moderate exercise on bowel habitGutYear: 19913289419441885077
187. Ueki A,Otsuka M. Life style risks of Parkinson’s disease: association between decreased water intake and constipationJournal of NeurologyYear: 2004251, supplement 71823
188. Bosshard W,Dreher R,Schnegg JF,Büla CJ. The treatment of chronic constipation in elderly people: an updateDrugs and AgingYear: 2004211491193015554750
189. Roberfroid MB. Health benefits of non-digestible oligosaccharidesAdvances in Experimental Medicine and BiologyYear: 19974272112199361846
190. Astarloa R,Mena MA,Sanchez V,de la Vega L,de Yebenes JG. Clinical and pharmacological effects of a diet rich in insoluble fiber on Parkinson’s diseaseClinical NeuropharmacologyYear: 1992153753801330307
191. Eichhorn TE,Oertel WH. Macrogol 3350/electrolyte improves constipation in Parkinson’s disease and multiple system atrophyMovement DisordersYear: 20011661176117711748757
192. Sakakibara R,Yamaguchi T,Uchiyama T,et al. Calcium polycarbophil improves constipation in primary autonomic failure and multiple system atrophy subjectsMovement DisordersYear: 200722111672167317149723
193. Sadjadpour K. Pyridostigmine bromide and constipation in Parkinson’s diseaseJournal of the American Medical AssociationYear: 19832499114811496823069
194. Dive A,Foret F,Jamart J,Bulpa P,Installe E. Effect of dopamine on GI motility during criticall illnessIntensive Care MedicineYear: 20002690190710990104
195. Marzio L,Neri M,Pieramico O,Delle Donne M,Peeters TL,Cuccurullo F. Dopamine interrupts gastrointestinal fed motility pattern in humans: effect on motilin and somatostatin blood levelsDigestive Diseases and SciencesYear: 19903533273321968372
196. Lanfranchi GA,Bazzocchi G,Fois F,Brignola C,Campieri M,Menni B. Effect of domperidone and dopamine on colonic motor activity in patients with the irritable bowel syndromeEuropean Journal of Clinical PharmacologyYear: 19852933073104076326
197. Hornykiewicz O,Kish SJ. Biochemical pathophysiology of Parkinson’s diseaseAdvances in Neurology Year: 19864519342881444
198. Bermejo Pareja F,Martinez-Martin P,Muradas V,de Yebenes JG. Carbidopa dosage modifies L-dopa induced side effects and blood levels of L-dopa and other amino acids in advanced parkinsonismActa Neurologica ScandinavicaYear: 19857255065114082917
199. Tonini M. Recent advances in the pharmacology of gastrointestinal prokineticsPharmacological ResearchYear: 1996334-52172268938012
200. Soykan M,Sarosiek I,Shifflett J,Wooten GF,McCallum RW. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson’s diseaseMovement DisordersYear: 19971269529579399220
201. Iyer SS,Morgan JC,Sethi KD. Absorption of orally disintegrating carbidopalevodopa requires intact small bowel functionNeurologyYear: 2005659p. 1507
202. Shindler JS,Finnerty GT,Towlson K,Dolan AL,Davies CL,Parkes JD. Domperidone and levodopa in Parkinson’s diseaseBritish Journal of Clinical PharmacologyYear: 19841869599626529536
203. Neira WD,Sanchez V,Mena MA,de Yebenes JG. The effects of Cisapride on plasma L-dopa levels and clinical response in Parkinson’s diseaseMovement DisordersYear: 199510166707885357
204. Langdon N,Malcolm PN,Parkes JD. Comparison of levodopa with carbidopa, and levodopa with domperidone in Parkinson’s diseaseClinical NeuropharmacologyYear: 1986954404473768866
205. Djaldetti R,Koren M,Ziv I,Achiron A,Melamed E. Effect of Cisapride on response fluctuations in Parkinson’s diseaseMovement DisordersYear: 199510181847885359
206. Jost WH,Schimrigk K. Long-term results with cisapride in Parkinson’s diseaseMovement DisordersYear: 19971234234259159740
207. Sempere AP,Duarte J,Cabezas C,Claveria LE,Coria F. Aggravation of parkinsonian tremor by cisaprideClinical NeuropharmacologyYear: 199518176788665538
208. Inui A,Yoshikawa T,Nagai R,Yoshida N,Ito T. Effects of mosapride citrate, a 5-HT4 receptor agonist, on colonic motility in conscious guinea pigsJapanese Journal of PharmacologyYear: 200290431332012501007
209. Asai H,Udaka F,Hirano M,et al. Increased gastric motility during 5-HT4 agonist therapy reduces response fluctuations in Parkinson’s diseaseParkinsonism and Related DisordersYear: 200511849950216263322
210. Liu Z,Sakakibara R,Odaka T,et al. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, amerliorates constipation in parkinsonian patientsMovement DisordersYear: 200520668068615719424
211. Iida H,Inada H,Tanaka H,Nagasaka T,Shindo K,Shiozawa Z. Effects of antiemetic drugs in combination with a dopamine receptor agonist, pergolide, on Parkinson’s disease: a comparison between domperidone and mosaprideNeurological TherapeuticsYear: 20021915762
212. Sullivan KL,Staffetti JF,Hauser RA,Dunne PB,Zesiewicz TA. Tegaserod (Zelnorm) for the treatment of constipation in Parkinson’s diseaseMovement DisordersYear: 200621111511616142776
213. Maganti K,Onyemere K,Jones MP. Oral erythromycin and symptomatic relief of gastroparesis: a systematic reviewAmerican Journal of GastroenterologyYear: 200398225926312591038
214. Pfeiffer RF,Markopoulou K,Quigley EMM,Stambler N,Cedarbaum JM. Effect of NT-3 on bowel function in Parkinson’s diseaseMovement DisordersYear: 20021722322411835473
215. Sandyk R,Gillman MA. Colchicine ameliorates constipation in Parkinson’s diseaseJournal of the Royal Society of MedicineYear: 19847712p. 1066
216. Albanese A,Maria G,Bentivoglio A,Brisinda G,Cassetta E,Tonali P. Severe constipation in Parkinson’s disease relieved by botulinum toxinMovement DisordersYear: 19971257647669380063
217. Cadeddu F,Bentivoglio AR,Brandara F,Marniga G,Brisinda G,Maria G. Outlet type constipation in Parkinson’s disease: results of botulinum toxin treatmentAlimentary Pharmacology and TherapeuticsYear: 20052210997100316268975
218. Chiarioni G,Heymen S,Whitehead WE. Biofeedback therapy for dyssynergic defecationWorld Journal of GastroenterologyYear: 200612447069707417131466
219. Papatsoris AG,Deliveliotis C,Singer C,Papapetropoulos S. Erectile dysfunction in Parkinson’s diseaseUrologyYear: 200667344745116504269
220. Brown E,Brown GM,Kofman O,Quarrington B. Sexual function and affect in parkinsonian men treated with L-dopaAmerican Journal of PsychiatryYear: 19781351215521555717578
221. Brown RG,Jahanshahi M,Quinn N,Marsden CD. Sexual function in patients with Parkinson’s disease and their partnersJournal of Neurology, Neurosurgery and PsychiatryYear: 1990536480486
222. Lipe H,Longstreth WT,Bird TD,Linde M. Sexual function in married men with Parkinson’s disease compared to married men with arthritisNeurologyYear: 1990409134713492392215
223. Welsh M,Hung L,Waters CH. Sexuality in women with Parkinson’s diseaseMovement DisordersYear: 19971269239279399216
224. Argiolas A,Melis MR. Central control of penile erection: role of the paraventricular nucleus of the hypothalamusProgress in NeurobiologyYear: 200576112116043278
225. Singer C,Weiner WJ,Sanchez-Ramos JR,Ackerman M. Sexual dysfunction in men with Parkinson’s diseaseJournal of Neurologic RehabilitationYear: 19893199204
226. van Furth WR,Wolterink G,van Ree JM. Regulation of masculine sexual behavior: involvement of brain opioids and dopamineBrain Research ReviewsYear: 19952121621848866673
227. Dominguez JM,Hull EM. Dopamine, the medial preoptic area, and male sexual behaviorPhysiology and BehaviorYear: 200586335636816135375
228. Tsujimura A,Miyagawa Y,Fujita K,et al. Brain processing of audiovisual sexual stimuli inducing penile erection: a positron emission tomography studyJournal of UrologyYear: 2006176267968316813919
229. Fisher C,Gorss J,Zuch J. Cycle of penile erection synchronous with dreaming (REM) sleepArchives of General PsychiatryYear: 196512294514221689
230. Hirshkowitz M,Schmidt MH. Sleep-related erections: clinical perspectives and neural mechanismsSleep Medicine ReviewsYear: 20059431132915994100
231. Langston JW,Forno LS. The hypothalamus in Parkinson diseaseAnnals of NeurologyYear: 197832129133350130
232. Ben Zion IZ,Tessler R,Cohen L,et al. Polymorphisms in the dopamine D4 receptor gene (DRD4) contribute to individual differences in human sexual behavior: desire, arousal and sexual functionMolecular PsychiatryYear: 20061178278616619053
233. Bellomo G,Santambrogio L,Fiacconi M,Scarponi AM,Ciuffetti G. Plasma profiles of adrenocorticotropic hormine, cortisol, growth hormone and prolactin in patients with untreated Parkinson’s diseaseJournal of NeurologyYear: 199123819221851513
234. Martin-Alguacil N,Schober J,Kow LM,Pfaff D. Arousing properties of the vulvar epitheliumJournal of UrologyYear: 2006176245646216813864
235. Martin-Alguacil N,Schober JM,Sengelaub DR,Pfaff DW,Shelley DN. Clitoral sexual arousal: neuronal tracing study from the clitoris through the spinal tractsJournal of UrologyYear: 200818041241124818707740
236. Munarriz R,Kim SW,Kim NN,et al. A review of the physiology and pharmacology of peripheral (vaginal and clitoral) female genital arousal in the animal modelJournal of UrologyYear: 20031702, part 2S40S4512853772
237. Pfaff D,Frohlich J,Morgan M. Hormonal and genetic influences on arousal—sexual and otherwiseTrends in NeurosciencesYear: 2002251455011801338
238. Gelez H,Poirier S,Facchinetti P,et al. Neuroanatomical evidence for a role of central melanocortin-4 receptors and oxytocin in the efferent control of the rodent clitoris and vaginaJournal of Sexual MedicineYear: 2010762056206720345736
239. Komisaruk BR,Whipple B. Functional MRI of the brain during orgasm in womenAnnual Review of Sex ResearchYear: 2005166286
240. Pedersen CA,Boccia ML. Oxytocin maintains as well as initiates female sexual behavior: effects of a highly selective oxytocin antagonistHormones and BehaviorYear: 200241217017711855901
241. Baskerville TA,Douglas AJ. Dopamine and oxytocin interactions underlying behaviors: potential contributions to behavioral disordersCNS Neuroscience and TherapeuticsYear: 2010163e92e12320557568
242. Graham MD,Pfaus JG. Differential regulation of female sexual behaviour by dopamine agonists in the medial preoptic areaPharmacology Biochemistry and BehaviorYear: 2010972284292
243. Frye CA,Walf AA. Infusions of anti-sense oligonucleotides for DARPP-32 to the ventral tegmental area reduce effects of progesterone- and a dopamine type 1-like receptor agonist to facilitate lordosisBehavioural Brain ResearchYear: 2010206228629219782104
244. Jacobs H,Vieregge A,Vieregge P. Sexuality in young patients with Parkinson’s disease: a population based comparison with healthy controlsJournal of Neurology, Neurosurgery and PsychiatryYear: 2000694550552
245. Bronner G,Royter V,Korczyn AD,Giladi N. Sexual dysfunction in Parkinson’s diseaseJournal of Sex and Marital TherapyYear: 20043029510514742099
246. Welsh M,Hung L,Waters CH. Sexuality in women with Parkinson’s diseaseMovement DisordersYear: 19971269239279399216
247. Wermuth L,Stenager E. Sexual problems in young patients with Parkinson’s diseaseActa Neurologica ScandinavicaYear: 19959164534557572039
248. MacLennan KM,Boshier A,Wilton LV,Shakir SAW. Examination of the safety and use of apomorphine prescribed in general practice in England as a treatment for erectile dysfunctionBJU InternationalYear: 200698112513116831156
249. O’Sullivan JD. Apomorphine as an alternative to sildenafil in Parkinson’s diseaseJournal of Neurology, Neurosurgery and PsychiatryYear: 2002725p. 681
250. Deleu D,Hanssens Y,Northway MG. Subcutaneous apomorphine: an evidence-based review of its use in Parkinson’s diseaseDrugs and AgingYear: 2004211168770915323576
251. Safarinejad MR. Salvage of sildenafil failures with cabergoline: a randomized, double-blind, placebo-controlled studyInternational Journal of Impotence ResearchYear: 200618655055816625231
252. Pohankaa M,Kanovsky P,Bares M,Pulkrabekb J,Rektorb I. The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson’s disease induced by pergolide: evidence from the results of an open, prospective, one-year trialParkinsonism and Related DisordersYear: 200511850951215994112
253. Klos KJ,Bower JH,Josephs KA,Matsumoto JY,Ahlskog JE. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson’s disease and multiple system atrophyParkinsonism and Related DisordersYear: 200511638138616109498
254. Kessel BL. A case of hedonistic homeostatic dysregulationAge and AgeingYear: 200635554054116799178
255. Castelli L,Perozzo P,Genesia ML,et al. Sexual well being in parkinsonian patients after deep brain stimulation of the subthalamic nucleusJournal of Neurology, Neurosurgery and PsychiatryYear: 200475912601264
256. Romito LM,Raja M,Daniele A,et al. Transient mania with hypersexuality after surgery for high-frequency stimulation of the subthalamic nucleus in Parkinson’s diseaseMovement DisordersYear: 20021761371137412465087
257. Hussain IF,Brady CM,Swinn MJ,Mathias CJ,Fowler CJ. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson’s disease or multiple system atrophy with observations on orthostatic hypotensionJournal of Neurology, Neurosurgery & Psychiatry Year: 2001713371374
258. Raffaele R,Vecchio I,Giammusso B,Morgia G,Brunetto MB,Rampello L. Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson’s diseaseEuropean UrologyYear: 200241438238612074807
259. Safarinejad MR,Hosseini SY. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled studyJournal of UrologyYear: 200817931066107118206919
260. Yang CC,Cao YY,Guan QY,et al. Influence of PDE5 inhibitor on MRI measurement of clitoral volume response in women with FSAD: a feasibility study of a potential technique for evaluating drug responseInternational Journal of Impotence ResearchYear: 200820110511018059502
261. Chivers ML,Rosen RC. Phosphodiesterase type 5 inhibitors and female sexual response: faulty protocols or paradigms?Journal of Sexual MedicineYear: 201072, part 285887219929916
262. Shadiack AM,Sharma SD,Earle DC,Spana C,Hallam TJ. Melanocortins in the treatment of male and female sexual dysfunctionCurrent Topics in Medicinal ChemistryYear: 20077111137114417584134

Article Categories:
  • Review Article

Previous Document:  A cognitive-perceptual approach to conceptualizing speech intelligibility deficits and remediation p...
Next Document:  The importance of psychological and social factors in influencing the uptake and maintenance of phys...